Aurisco Pharmaceutical Co.,Ltd. (SHA:605116)

Market Cap	8.56B
Revenue (ttm)	1.54B
Net Income (ttm)	392.03M
Shares Out	406.20M
EPS (ttm)	0.99
PE Ratio	21.25
Forward PE	16.40
Dividend	0.29 (1.38%)
Ex-Dividend Date	Jun 6, 2024

Volume	1,712,089
Average Volume	2,300,265
Open	21.08
Previous Close	21.08
Day's Range	20.95 - 21.23
52-Week Range	18.70 - 26.99
Beta	-0.16
RSI	49.10
Earnings Date	Aug 29, 2025

About Aurisco Pharmaceutical

Aurisco Pharmaceutical Co.,Ltd. engages in research, manufacturing, and marketing of pharmaceutical intermediates, specialty active pharmaceutical ingredients (API’s), and formulations catering to the pharmaceutical market worldwide. The company offers APIs and intermediates of respiratory system, cardiovascular, anti-infection, nervous system, anti-tumor, and women's health drugs. It also provides dexamethasone is used to treat skin diseases; fluticasone propionate preparations are used to treat asthma and allergic rhinitis; fluticasone furoat...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1998
• Employees: 1,784
• Stock Exchange: Shanghai Stock Exchange
• Ticker Symbol: 605116

Financial Performance

In 2024, Aurisco Pharmaceutical's revenue was 1.48 billion, an increase of 16.89% compared to the previous year's 1.26 billion. Earnings were 354.79 million, an increase of 22.59%.